BBHVanEck Biotech ETF

Grow my money14y track recordRanked #984 of 3,055 in this goal

Seeks to replicate the price and yield performance of the MVIS US Listed Biotech 25 Index.

By VanEck · Launched 2011

Annual Cost

0.35%

#1,699 of 6,040 · low cost

Fund Size

$400M

#1,835 of 6,040 · large

Return (1Y)

+33.0%

Track Record

14 years

#944 of 6,040 · established

Performance

Total-return NAV · USD

Growth of $10,000

$11,682+16.8%

Total-return NAV, USD. Net of fund fees, before tax.

What's inside

How Beacon categorizes this fund

Asset class

Equity

Region

North america

Cap

Mid

Strategy

Index tracking

Sector

Health care

Focus

Biotech & Genomics

Index tracked

MVIS US Listed Biotech 25 Index

Holdings

By weight

Concentration

Top 10 holdings = 70.8% of fundconcentrated

Gilead Sciences Inc

14.6%

Amgen Inc

14.5%

Vertex Pharmaceuticals Inc

8.1%

Regeneron Pharmaceuticals Inc

7.5%

Argenx SE

5.3%

Insmed Inc

4.6%

IQVIA Holdings Inc

4.3%

Alnylam Pharmaceuticals Inc

4.1%

Natera Inc

4.0%

United Therapeutics Corp

3.8%

Asset allocation

Stocks

100.0%

Cash

0.0%

By sector

Healthcare

100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

19.3%Moderate

Year-on-year price swings

Max drawdown

-39.9%Severe

Worst peak-to-trough loss

Sharpe (3Y)

0.46Below average

Sortino (3Y)

0.65Moderate downside risk

Listing

Exchange: NASDAQ Global Select Market

Full fund details

Objective: Seeks to replicate the price and yield performance of the MVIS US Listed Biotech 25 Index.
Strategy: Uses a passive investment approach to replicate the MVIS US Listed Biotech 25 Index by investing at least 80% of total assets in common stocks and depositary receipts of U.S. biotechnology companies. The Fund may concentrate its investments in the biotechnology industry, which includes companies with market capitalizations between approximately $9.16 billion and $176.26 billion.
Inception date: December 20, 2011
Fund family: VanEck